A shortage listing ends. 16 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Shortage listings
Page 3 of 13 of this archive, newest first.
A shortage listing ends. 7 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 10 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
Randomised withdrawal is the cleanest design in this field and the least discussed
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
The 27-day notice: how a compounding wind-down works in the United Arab Emirates
The document is four pages. Three of them are about dates.
A shortage listing ends. 23 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 29-day notice: how a compounding wind-down works in India
The document is four pages. Three of them are about dates.
A shortage listing ends. 24 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 12-day notice: how a compounding wind-down works in Italy
The document is four pages. Three of them are about dates.
A shortage listing ends. 17 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 6-day notice: how a compounding wind-down works in South Africa
The document is four pages. Three of them are about dates.
Side effects, cost, supply, target: four reasons with four trajectories
The trials studied planned withdrawal. Almost nobody stops that way.
A shortage listing ends. 18 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 25-day notice: how a compounding wind-down works in France
The document is four pages. Three of them are about dates.
The shortage years, and what they taught about interruption
Why the reason for stopping changes what happens afterwards.
What SURMOUNT-3 tells us about maintenance, and what it does not
The commonest real-world strategy in this drug class is the least studied one.
The withdrawal trials, read as designs rather than warnings
Three randomised withdrawal designs have tested what happens when treatment stops. Their results are consistent and they are consistently misreported.
A shortage listing ends. 23 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
A shortage listing ends. 20 pharmacies now have a business model and no legal basis for it.
The document is four pages. Three of them are about dates.
The 26-day notice: how a compounding wind-down works in Ireland
The document is four pages. Three of them are about dates.